



Delivering Accurate Diagnosis of Growth Disorders

Clinical Significance of Growth Hormone (GH), Insulin-like Growth Factor I (IGF-I), and Insulin-like Growth Factor Binding Protein 3 (IGFBP-3)

[siemens-healthineers.com](https://www.siemens-healthineers.com)

Understanding Growth Hormone Interaction

Growth hormone (GH) is secreted from the pituitary gland. These secretions fluctuate in a circadian pattern over the course of a day, peaking about 1 hour after the onset of nightly sleep, and are lowest during the day. GH production is stimulated in a pulsatile manner predominantly during sleep under the influence of hypothalamic hormones, but also can be stimulated to a small extent by exercise. As a result of these irregular secretions, the information acquired from a single GH result is very limited. In the past, a series of GH samples collected over a 24-hour period was used to determine GH status.¹ This is not a practical diagnostic procedure in any clinical setting; therefore, current practice usually involves the use of GH provocation testing.

Insulin-like growth factor I (IGF-I) and circulating insulin-like growth factor binding protein 3 (IGFBP-3) mediate the growth-inducing functions of GH. Both are regulated by GH but do not exhibit daily fluctuations. IGF-I and IGFBP-3 can be useful serological markers that can aid in the diagnosis of GH dysfunctions, GH deficiencies (GHD), and acromegaly. Both IGF-I and IGFBP-3 can also be used as good surrogate markers for monitoring recombinant human GH (rhGH) and IGF-I replacement therapies. GH provocation testing, along with IGF-I and IGFBP-3 baseline measurements, assists endocrinologists in diagnosing growth conditions.



Growth hormone interactions

Understanding the details of the complex hormone interactions of the growth hormone/insulin-like growth factor axis (Figure 1) is critical in the diagnosis and treatment of growth disorders.¹ Growth hormone-releasing hormone (GHRH) is released from the hypothalamus to stimulate the pituitary gland to release GH. Somatotropin release-inhibiting factor (SRIF) is also secreted by the hypothalamus and inhibits the GH release. These two factors constantly up- and down-regulate the release of GH, causing pulsatile secretion throughout the day.^{1,2} Deep sleep induces more secretions in higher concentrations, generating a primarily nocturnal secretory pattern.

The up-regulation of GH triggers IGF-I synthesis in the liver and, to a lesser extent, in peripheral cells. IGF-I mediates the growth-promoting actions of GH through both autocrine and paracrine signaling. This accounts for the broad range of physiological actions of IGF-I.³ IGF-I circulates bound to one of six binding proteins (IGFBPs). IGFBP-3 has a high affinity to IGF-I and is the most abundant of these binding proteins, accounting for the predominance of IGF-I circulates bound to IGFBP-3.

After the IGF-I and IGFBP-3 complex is formed, it further associates with the acid-labile subunit (ALS). The IGF-I/IGFBP-3/ALS complex preserves protein conformation and increases the half-life of circulating IGF-I, making it available for future use. IGF-I can also be released from the binding proteins by a specific IGFBP protease reaction.³




Figure 1. Growth hormone/insulin-like growth factor axis.²

Diagnostic Growth Assays

The irregular GH production cycle makes a single, random measurement ineffective in diagnosing GHD. The most useful GH measurements are associated with GH provocation tests for diagnosing GHD. Numerous pharmacological agents are used in the GH provocation tests, such as insulin, arginine, and GHRH. The GH provocation tests require that the patient fast for 10 to 12 hours prior to administering the provocative agent. Afterward, the GH is sampled for several hours to monitor the change in GH. These tests are expensive and time-consuming, do not have well-established intervals or cutoffs, and introduce additional risk to the patient. Despite these shortcomings, the GH provocation tests are a direct means of probing GHD.

IGF-I and IGFBP-3 levels show only minor fluctuations throughout the day, in contrast to the circadian variations that GH displays. The stable serum readings of IGF-I and IGFBP-3 can be thought of as an integrated measurement of GH secretions. GHD and GH-resistance patients typically have low IGF-I and IGFBP-3 concentrations. These measurements should be compared to the age-based reference intervals that have been determined for these assays.⁴


An overproduction of GH is most frequently caused by a GH-secreting pituitary tumor and may present clinically as acromegaly or gigantism. When a GH excess is suspected, an oral glucose tolerance test is the best means of directly measuring GH. This is an expensive and time-consuming test that requires the patient to fast and have multiple samples drawn.

However, cutoffs for diagnosing acromegaly and gigantism are more established using this method. Elevated IGF-I and IGFBP-3 levels are also indicative of GH overproduction.

IGF-I is produced in the liver and mediates many of the GH biological functions. It serves as an important signal, transmitting the GH secretion and nutritional status to various cells. Additional stimuli of IGF-I should be taken into consideration, as they could significantly alter a patient's results and lead to falsely reduced or elevated values. Table 1 lists confounding conditions that may increase or decrease IGF-I levels.

Table 1. Confounding conditions that affect IGF-I levels.

Reduced IGF-I Levels	Increased IGF-I Levels
Malnutrition/ malabsorption	Precocious puberty
Hypothyroidism	Obesity
Liver disease	Kidney disease (dialysis)
Liver disease	
Chronic inflammatory disease	
Malignant disease	
Multiple injuries	



Importance of Growth Hormone Assays

GH, IGF-I, and IGFBP-3 results are essential when diagnosing and treating growth disorders. The Siemens Healthineers GH assay is very specific and sensitive and requires only a small volume of sample. Siemens Healthineers IMMULITE® 2000/XPi IGF-I and IGFBP-3 assays have established age- and gender-based reference intervals that are crucial in assessing the patient's growth condition. Our IMMULITE 2000/XPi IGF-I assay is standardized to the WHO 1st International Standard 02/254 for IGF-I with newly established detection limits (LoD and LoQ), ensuring confidence in your laboratory's test results.

Excessive Growth and Growth Hormone Deficiency

Excessive action of IGF-I while epiphyseal growth plates are open causes gigantism,⁵ which occurs very rarely. Children and adolescents with gigantism stand >2 standard deviations above the mean height for their gender and age.

Acromegaly is also caused by hypersecretion of IGF-I.⁵ In contrast to gigantism, it occurs in adolescence and adults after their epiphyseal growth plates have fused. Acromegaly in adults is the most common disorder of GH excess, with an estimated prevalence of between 45 and 120 per million.⁶ Visible signs of acromegaly and gigantism are enlarged hands and feet, in addition to larger and broader facial features. These conditions are most often caused by a GH-secreting pituitary adenoma, or less frequently by ectopic causes of GH release, and are commonly treated by surgery, radiation therapy, and the use of a GH receptor antagonist.

The initial tests for GH excess are a fasting or random GH and IGF-I. According to the Acromegaly Consensus Group statement,⁷ acromegaly can be excluded if either of the following sets of tests results are observed:⁷

- Random GH <0.4 µg/L and IGF-I is normal, or
- Oral glucose tolerance test results of <1 µg/L in addition to normal GH and IGF-I values

The consensus statement⁷ clearly points out that the IGF-I value must be compared to a reference interval that is age- and gender-appropriate for the patient.

The publication also defines criteria for treatment outcomes (controlled, inadequate control, and poor control) based on GH, IGF-I, and MRI data. As an example, the controlled treatment outcome criteria are as follows:

- Nadir GH <1.0 µg/L
- IGF-I normal (vs. age-gender reference interval)
- No clinical activity observed by MRI



Growth hormone deficiency in children

Often when a child is taken to a doctor for evaluation of growth hormone deficiency (GHD), the family is concerned about the child's lack of size and physical development. Two terms that are commonly used in treating patients who have not met their growth targets are growth failure and short stature. Short stature is defined by the child's height being <2 standard deviations below the mean (or approximately the 3rd percentile). Many children with short stature actually have normal growth velocity. Growth failure, however, describes a growth rate below the appropriate growth velocity for age based on normal growth rates.^{8,9}

Table 2. GH-IGF disturbances that cause short stature or growth failure.¹⁰⁻¹³

Clinical Presentation	Site of Disturbance	GH Axis	IGF-I Axis
Hypothalamic Tumor	Hypothalamus	Decrease	–
Hypothyroidism		–	Decrease
Pituitary Tumor	Pituitary Gland	Decrease	–
Abnormal GH Variant		–	Decrease
Laron Syndrome (GH Receptor Defect)	IGF-I Local Production	Increase	Decrease
Pygmies		Normal	Decrease
Glucocorticoid-induced GHD	Cartilage	Normal	Normal
IGF-I Resistance		Normal	Increase

When a child presents with a history of slow growth that suggests GHD, the physician should evaluate the patient for other causes of growth failure, such as hypothyroidism, chronic systemic disease, Turner syndrome, and skeletal disorder.¹³ After these conditions have been ruled out, the child should be screened for a GH/IGF-I deficiency. The consensus document on GH therapy for children and adolescents¹³ calls for a single GH provocation test when the patient presents with defined central nervous system pathology, history of irradiation, multiple pituitary hormone deficiencies (MPHD), or a genetic defect (Table 2). If isolated GHD is suspected, it is recommended that two GH provocation tests be conducted.

In practice, IGF-I and IGFBP-3 are often measured initially, so the possibility of GHD can be evaluated before subjecting children to GH provocation testing. Provocation tests are not only costly and time-consuming, but some can also put children in jeopardy. Additionally, provocation tests do not have well-established, assay-specific reference values and cutoffs.

Child dosing and maintenance guidelines

In children, the principal measure of successful GH therapy is the increase in the patient's height and growth velocity.¹³ IGF-I and IGFBP-3 levels are monitored routinely during therapy to confirm GH dosage is sufficient; serological monitoring can also help assess patient compliance. Additional patient monitoring is essential to check for potential negative side effects, such as intracranial hypertension. The 2000 consensus guideline states that the GH dose should be 25 to 50 µg/kg/day delivered intramuscularly, with dose adjustments made for obese children.¹³ Recently, Cohen et al.¹⁴ published a randomized, controlled study that achieved improved growth response by titrating individualized GH dose. This type of dosing requires that the initial dose be adjusted based on the IGF-I and IGFBP-3 levels.

Adult Growth Hormone Deficiency

The diagnosis of adult growth hormone deficiency (AGHD) is often difficult because the patient is fully grown, and height is no longer an indication of the condition. Therefore, the physician must rely on biomarkers to identify adults who have GHD. The most common causes of AGHD are:

- Hypothalamic-pituitary disorders
- Childhood-onset GHD
- Previous cranial ablation
- Traumatic brain injuries

The suspicion of GHD is heightened when other pituitary hormone deficiencies are present.¹³ These patients often have a higher incidence of cardiovascular disease and reduced bone mass, which increases their risk of fractures. AGHD is also associated with reduced lean body mass with concomitant decreased physical strength and increased fatty tissue (especially central obesity), which can lead to metabolic disease, reduced quality of life, anxiety, and depression.

Tests to diagnose GHD include measurement of GH using provocation tests and measurement of IGF-I. As with children, the GH provocation tests do not have well-established cutoffs and can cause some risk to the patient. One consensus document¹³ outlines the limitations of these tests. Consensus documents also recommend that IGF-I is a good initial screening test when GHD is suspected in patients who are over 40 years old and have a body mass >25 kg/m.¹³

As stated in a 2007 consensus document,¹³ "Not all patients suspected of having GHD, however, require a GH stimulation test for diagnosis. Patients with three or more pituitary hormone deficiencies and an IGF-I level below the reference range have >97% chance of being GHD, and therefore do not need a GH stimulation test."¹³ This is further supported in a publication by Kwan et al.,¹⁵ in which an algorithm for AGHD testing is proposed (Figure 2).

Adult dosing and maintenance guidelines

IGF-I and IGFBP-3 are useful markers for titrating an individual patient's dose. Normally, the initial dose is 0.1 mg GH/day for older patients, 0.2 mg GH/day for younger men, and 0.3 mg GH/day for women. After 6 weeks, IGF-I and IGFBP-3 are measured to optimize the therapy; the dose is adjusted so the IGF-I and IGFBP-3 concentrations are slightly below the age- and gender-related upper limit of the reference interval.¹³ Once the individual's dose is established, monitoring must take place annually or if changes in dosing are made.




Figure 2. Algorithm used to determine what screening is necessary to diagnose AGHD as described in literature.¹³

*PHDs: pituitary hormone deficiencies

References

1. Melmed S, Jameson JL. Disorders of the anterior pituitary and hypothalamus. In: Principles of Endocrinology. Jameson JL editor. New York: McGraw-Hill; 2006. p. 19-56.
2. Roelfsema V, Clark RG. The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure. *J Am Soc Nephrol*. 2001;12:1297-1306.
3. Bayes-Genis A, Conove, CA, Schwatz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. *Circ Res*. 2000;86:125-30.
4. Reference ranges for serum IGF-I; 2017. Available from: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0185561>
5. Ferry, RJ. Giantism and acromegaly. eMedicine Specialties [Internet]: 2010 July. <http://emedicine.medscape.com/article/925446-overview>
6. Prevalence of acromegaly. 2016. Available from: <https://link.springer.com/article/10.1007/s11102-016-0725-2>
7. Giustina A, Barkan A, Felipe F, Casanueva FC, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. *J Clin Endocrinol Metab*. 2000;85:526-9.
8. Kemp S. Growth failure [Internet]. eMedicine Specialties; 2009 Sep. Available from: <http://emedicine.medscape.com/article/920446-overview>
9. Kemp S. Growth failure [Internet]. eMedicine Specialties; 2009 Sep. Available from: <http://emedicine.medscape.com/article/924411-overview>
10. Blum WF, et al. The growth hormone–insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. *Endocrine Connections*. 2018;7:R212–22.
11. Johannsson G, et al. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. *Endocrine Connections*. 2018. Available from: <https://doi.org/10.1530/EC-18-0047>.
12. Roelfsema V, Clark RG. The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure. *J Am Soc Nephrol*. 2000;12:1297-1306.
13. GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence. *J Clin Endocrinol Metab*. 2000;85:3990-3.
14. Insulin growth factor-I-based dosing of growth hormone therapy in children: a randomized, controlled study. 2009. Available from: <https://pubmed.ncbi.nlm.nih.gov/31569898/>
15. Kwan AYM, Hartman ML. IGF-I measurements in the diagnosis of adult growth hormone deficiency. *Pituitary*. 2007;10:151-7.

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.

Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world's most threatening diseases, improving the quality of outcomes, and enabling access to care.

We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what's possible in healthcare to help improve people's lives around the world.

IMMULITE and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.

Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

Siemens Healthineers Headquarters

Siemens Healthcare GmbH
Henkestr. 127
91052 Erlangen, Germany
Phone: +49 9131 84-0
siemens-healthineers.com

Published by

Siemens Healthcare Diagnostics Inc.
Laboratory Diagnostics
511 Benedict Avenue
Tarrytown, NY 10591-5005
USA
Phone: +1 914-631-8000